期刊文献+

中晚期非小细胞肺癌化疗前后二乙酰精胺的变化 预览 被引量:1

Changes of diacetylspermidine before and after chemotherapy in advanced non-small cell lung cancer
在线阅读 下载PDF
收藏 分享 导出
摘要 目的 探讨尿液二乙酰精胺(DAS)水平评价非小细胞肺癌(NSCLC)化疗疗效指标的可行性.方法 选取首次接受治疗的中、晚期NSCLC患者78例,采用含铂两药联合化疗2个疗程.每疗程结束后3周评价疗效并检测DAS水平、尿肌酐校正(Ucr).结果 78例患者全部完成实验,第1疗程疾病控制率(DCR)为75.64%,第2疗程DCR为87.18%.第1疗程后DAS水平与化疗前比较显著下降[(1.83±0.30)mmol/mL/g Ucr vs.(2.17±0.36)mmol/mL/g Ucr,P<0.01];第2疗程DAS较第1疗程继续显著下降[(1.35±0.19)mmol/mL/g Ucr vs.(1.83±0.30)mmol/mL/g Ucr,P<0.01].第1疗程化疗有效患者DAS与无效患者比较显著下降[(1.62±0.37)mmoL/mL/Ucr vs.(2.25±0.35)mmol/mL/g Ucr,P<0.01];第2疗程化疗有效患者DAS较无效患者也显著下降[(1.21±0.21)mmol/mL/g Ucr vs.(1.62±0.37)mmol/mL/g Ucr,P<0.01].2个疗程化疗无效患者DAS比较,差异无统计学意义(P>0.05).结论 中、晚期NSCLC患者化疗效果与尿液DAS水平具有良好的相关性,DAS可作为评价NSCLC化疗疗效的良好指标. Objective This study was designed to research the reliability to use urine diacetylspermine(DAS) in the assessment of chemotherapy effect for non-small cell lung cancer(NSCLC) patients.Methods Seventy eight advanced NSCLC patients who received initialtreatment were selected in this study.Platinum-based doublet chemotherapy was applied for two cycles therapy,with a week for each cycle.Three weeks after each therapy cycle,therapy effects were assessed and urine DAS content(modified with urine creatinine,Ucr) was determined.Results All of the 78 patients finished the study.The disease control rate(DCR) in first cycle therapy was 75.64%,and 87.18% in second cycle therapy.Urine DAS in first-chemotherapy patients was significantly decreased than in pre-chemotherapy[(1.83±0.30) mmol/mL/g Ucr vs.(2.17±0.36)mmoL/ mL/g Ucr,P〈0.01].Urine DAS content in second cycle chemotherapy patients continued to decrease notably compared with that in first cycle therapy[(1.35±0.19) mmol/mL/g Ucr vs.(1.83±0.30) mmol/mL/g Ucr,P〈0.01].Urine DAS was markably decreased in curative patients in first cycle therapy than in patients without curative effects[(1.21±0.21)mmol/mL/g Ucr vs.(1.62±0.37) mmol/mL/g Ucr,P〈0.01].In second cycle therapy,urine DAS content in curative patients was also decreased notably compared with that in patients without curative effects[(1.62±0.37)mmol/mL/g Ucr vs.(2.25±0.35) mmol/mL/g Ucr,P〈0.01].No significant difference was found between no-curative patients in two cycle chemotherapy(P〉0.05).Conclusion Chemotherapy effect correlates well with urine DAS content in advanced NSCLC patients.Urine DAS content can be used as a biomarker to monitor curative effect of chemotherapy for advanced NSCLC patients.
作者 贺旭东 刘峰 宫晓丽 周占文 HE Xudong1 ,LIU Feng2 ,GONG Xiaoli2 ,ZHOU Zhanwen3 (1. Clinical Laboratory Center ,Affiliated hospital of Liaoning University of Traditional Chinese Medicinet , Shenyang, Liaoning 110032, China; 2. Technological Department of Liaoning MEDI Biotechnology Company, Benxi, Liaoning 117004, China ; 3. Clinical Image Center,Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shen yang , Liaoning 110032, China)
出处 《检验医学与临床》 CAS 2017年第14期2045-2047,共3页 Laboratory Medicine and Clinic
关键词 二乙酰精胺 非小细胞肺癌 化疗疗效 diacetylspermine non-small cell lung cancer chemotherapy effect
作者简介 贺旭东,男,副主任医师,主要从事临床生化检验研究。 通信作者,E—mail:623701972@qq.com。
  • 相关文献

同被引文献8

引证文献1

二级引证文献3

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈